Omeros Corporation (OMER) Message Board

As I said before the stock market is really a function of supply and demand. We can't control how much others want the stock but we can affect the supply as their is a finite quantity of shares available. Hold tight to your shares until you see the full valuation of this drug platform. The manipulators have controlled this stock for last 3 yrs by preying on fears/rumors - this was trading closer to $14 less than 2yrs ago before the BS about safety/clinical hold. We knew that was not true and this has been confirmed with FDA lifting the hold and subsequent dog safety studies. The shorts/funds that wanted to steal shares used these fears to drive the stock even to below $3 last summer. Now we can see how they manipulate stock to their adavntage and get your shares. As for valuation, I think at a minimum this platform should currently be valued closer to $500-$700 MM mkt cap. Once the ph3 clinical trials in CF come out - you will see the validation of the drug platform and analysts and investors look at the mkt for both CF and NTM - then it is my feeling that we will see a rapid increase in valuation $1B plus as there are other applications in pulmonary and other settings using this technology. I have also said that it will be obvious when the institutions come for your shares - like going through eye of needle when shares are not available for sale. I say that we have been screwed for years in the valuation of this company - now that we are closer to catalysts/validation lets turn the tables on the manipulators and make them pay fair value for the shares....=) Apologize in advance for the long msg.

Like to get back over $10 - where this should be....=)
Upcoming phase 3 data in July for Cystic Fibrosis pulmonary infections - Vrtx spiked up over $5B im mkt cap on their phase 2 CF data. INSM data looks more impressive. Plus they will be added to Russell Index in mid June (Index funds need to buy over 3 million shares bfore then...). Look for this to start taking off soon....=)

Check out Insmed (INSM) also, breaking out new 52 wk high on heavy volume. Like the prospects of their upcoming phase 3 trials in July for infections from cystic fibrosis. Their ph2 results were more impressive than VRTX, which increased by $6B in mkt cap on similar results for CF. INSM stock will also be added to Russell index (index funds have to buy 4 mil shrs before mid June). Think stock will be over $17 in next 3 months....

Anyone own INSM - breaking out on volume. Like their prospects for pos outcome for ph3 trial in cystic fibrosis infections. Like their phase 2 CF data - VRTX also had positive phase 2 recently and mkt cap went up by $5B.... Also like that INSM will be added to Russell index in june (Index funds need to buy 4 mil shares before mid June.....=)

I 'd rather they cover when we are double digits....As I said before they big biys are going to take over and continue to add on upcoming positive data and news....=)

INSM going to have ph3 data in July for infections related to cystic fibrosis (VRTX went up $6B on their ph3 CF data). INSM data look more impressive. Also look for addition to Russel index (Index funds need to buy 4 mil shrs before mid June). This should be double digits soon...

Upcoming phase 3 data in July for Cystic Fibrosis pulmonary infections - Vrtx spiked up over $5B im mkt cap on their phase 2 CF data. INSM data looks more impressive. Plus they will be added to Russell Index in mid June (Index funds need to buy over 3 million shares bfore then...). Look for this to start taking off soon....=)

Upcoming phase 3 data in July for Cystic Fibrosis pulmonary infections - Vrtx spiked up over $5B im mkt cap on their phase 2 CF data. INSM data looks more impressive. Plus they will be added to Russell Index in mid June (Index funds need to buy over 3 million shares bfore then...). Look for this to start taking off soon....=)

Why wouldn't you lock in some profits- stock spiked over $6B on phase 2 data for CF. Spike also related to short covering and other trading dynamics. Sold some shares here also- no choice on that kind of move with blue chip biotech. Added to my large position in INSM - upcoming phase 3 data also in CF in July. Mkt cap is still small under $250MM mkt cap so lots of upside as they also have phase 2 data in the FAll in NTM pulmonary infections. . Stock will also be added to Russell Index in June (Index guys have to buy over 3 mil shrs before June...).

Shorts are just getting too desperate. If they were confident in BK they would want to actually let the buyers bid up so they can short more. This will be restructured and sold imo...=)